Apotex
Apotex Inc., a leading Canadian pharmaceutical company, is headquartered in Toronto, Ontario, Canada. Founded in 1974, Apotex has established itself as a key player in the global generic and specialty pharmaceuticals industry, with a strong presence in North America, Europe, and other international markets. The company is renowned for its extensive portfolio of over 300 generic medications, which are designed to provide affordable alternatives to brand-name drugs. Apotex's commitment to quality and innovation has led to significant milestones, including the development of complex generics and biosimilars. With a robust manufacturing infrastructure and a focus on research and development, Apotex has achieved a notable market position, consistently ranking among the top generic drug manufacturers in Canada and worldwide. Its dedication to improving patient access to essential medications underscores its reputation as a trusted leader in the pharmaceutical sector.
DitchCarbon Score
How does Apotex's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Apotex's score of 28 is lower than 50% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Apotex's reported carbon emissions
In 2023, Apotex reported total carbon emissions of approximately 40,219,000 kg CO2e for Scope 1 and about 15,572,000 kg CO2e for Scope 2. This reflects a decrease from 2022, where emissions were approximately 42,950,000 kg CO2e for Scope 1 and about 16,173,000 kg CO2e for Scope 2. Over the past few years, Apotex has shown a commitment to reducing its carbon footprint, with emissions from Scope 1 and 2 decreasing from 2021 levels of approximately 42,612,000 kg CO2e and 18,969,000 kg CO2e, respectively. Apotex is currently evaluating potential pathways to decarbonisation, aiming to set near-term emissions reduction targets for both Scope 1 and Scope 2 emissions by 2025. This initiative is part of their broader commitment to achieving net-zero emissions, although specific percentage reduction targets have not yet been established. The emissions data is cascaded from their parent company, Apotex Inc., indicating a corporate family relationship that influences their sustainability reporting and climate commitments. Apotex's ongoing efforts reflect a proactive approach to addressing climate change within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 44,817,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 20,870,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Apotex is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
